BioWorld

Dec. 13, 2005

View Archived Issues

Myogen Riding High After Preliminary PAH Findings

Positive Phase III news sent Myogen Inc.'s stock soaring 40.5 percent, with top-line data demonstrating ambrisentan's ability to improve symptoms of pulmonary arterial hypertension. (BioWorld Today) Read More

Pain Therapeutics Quitting IBS Drug On Phase III Miss

Read More

Gemin X's GX15-070: 'Hints Of Efficacy' In Phase I Work

Read More

GlycoFi's Largest-Ever Alliance: Potential $100M Via Merck Deal

Read More

Other News To Note

Read More